Guanhao BiotechLtd Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Guanhao BiotechLtd ha un patrimonio netto totale di CN¥471.1M e un debito totale di CN¥84.1M, che porta il suo rapporto debito/patrimonio netto a 17.8%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥730.3M e CN¥259.2M. L'EBIT di Guanhao BiotechLtd è CN¥9.4M rendendo il suo rapporto di copertura degli interessi -12.1. Ha liquidità e investimenti a breve termine pari a CN¥106.6M.

Informazioni chiave

17.8%

Rapporto debito/patrimonio netto

CN¥84.08m

Debito

Indice di copertura degli interessi	-12.1x
Contanti	CN¥106.65m
Patrimonio netto	CN¥471.07m
Totale passività	CN¥259.25m
Totale attività	CN¥730.32m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Solid Earnings May Not Tell The Whole Story For Guanhao BiotechLtd (SZSE:300238)

Nov 04

Subdued Growth No Barrier To Guanhao Biotech Co.,Ltd. (SZSE:300238) With Shares Advancing 38%

Oct 24

Optimistic Investors Push Guanhao Biotech Co.,Ltd. (SZSE:300238) Shares Up 28% But Growth Is Lacking

Sep 02

Guanhao Biotech Co.,Ltd. (SZSE:300238) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Jun 07

Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 26% Share Price Plunge Could Signal Some Risk

Apr 23

Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 32% Share Price Surge Not Quite Adding Up

Mar 09

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥273.6M ) di 300238 superano le sue passività a breve termine ( CN¥164.3M ).

Passività a lungo termine: Le attività a breve termine di 300238 ( CN¥273.6M ) superano le sue passività a lungo termine ( CN¥95.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 300238 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 300238 si è ridotto da 25.2% a 17.8% negli ultimi 5 anni.

Copertura del debito: Il debito di 300238 è ben coperto dal flusso di cassa operativo ( 31.6% ).

Copertura degli interessi: 300238 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Guanhao BiotechLtd Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Beijing Century TianFu Venture Capital Centre (Limited Partnership) acquired 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. for CNY 85.4 million.

Beijing Century TianFu Venture Capital Centre (Limited Partnership) acquired 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. for CNY 85.4 million.

Solid Earnings May Not Tell The Whole Story For Guanhao BiotechLtd (SZSE:300238)

Third quarter 2024 earnings released: EPS: CN¥0.023 (vs CN¥0.04 in 3Q 2023)

Subdued Growth No Barrier To Guanhao Biotech Co.,Ltd. (SZSE:300238) With Shares Advancing 38%

Guanhao Biotech Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Optimistic Investors Push Guanhao Biotech Co.,Ltd. (SZSE:300238) Shares Up 28% But Growth Is Lacking

Second quarter 2024 earnings released: EPS: CN¥0.027 (vs CN¥0.037 in 2Q 2023)

Guanhao Biotech Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Guanhao Biotech Co.,Ltd. (SZSE:300238) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.08 in 1Q 2023)

Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 26% Share Price Plunge Could Signal Some Risk

Investor sentiment deteriorates as stock falls 18%

Guanhao Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Guanhao Biotech Co.,Ltd.'s (SZSE:300238) 32% Share Price Surge Not Quite Adding Up

Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 26, 2024

Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 26, 2024

Full year 2023 earnings released: EPS: CN¥0.12 (vs CN¥1.16 loss in FY 2022)

Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 06, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.046 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.037 (vs CN¥1.03 loss in 2Q 2022)

Guanhao Biotech Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Guanhao Biotech Co.,Ltd. Announces Management Appointments

Full year 2022 earnings released: CN¥1.16 loss per share (vs CN¥0.28 profit in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.046 (vs CN¥0.08 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥1.03 loss per share (vs CN¥0.08 profit in 2Q 2021)

Investor sentiment improved over the past week

High number of new and inexperienced directors

Guanhao Biotech Co.,Ltd., Annual General Meeting, May 18, 2022

First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.07 in 1Q 2021)

Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.04 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.062 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.04 in 1Q 2020)

Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 30, 2021

New 90-day low: CN¥18.95

Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥1.75 loss in FY 2019)

New 90-day low: CN¥19.36

Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 09, 2021

New 90-day low: CN¥22.15

New 90-day high: CN¥29.88

New 90-day high: CN¥29.30

New 90-day low: CN¥23.15

Third quarter earnings released

Guanhao Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Guanhao Biotech Co.,Ltd. (SZSE:300238) intends to acquire 31% stake in ZY Therapeutics Inc. from U.S.TIANYOU CAPITAL CORP for $3.1 million.

New 90-day high - CN¥38.39

Guanhao Biotech Co.,Ltd. to Report First Half, 2020 Results on Jul 21, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane